Prelude Capital Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Prelude Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,700	Closed	-$5K	–	2025
2016 Q4	$5K	Buy	+3,700	New	+$6.43K	﹤0.01%	1449
2014 Q2	–	Sell	-3,000	Closed	-$53K	–	2511
2014 Q1	$53K	Buy	3,000 +1,287	+75%	+$24.9K	0.01%	1291
2013 Q4	$31K	Sell	1,713 -1,500	-47%	-$28.3K	0.01%	1273
2013 Q3	$86K	Sell	3,213 -1,087	-25%	-$23.3K	0.01%	825
2013 Q2	$79K	Buy	+4,300	New	+$75.9K	0.02%	761

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Prelude Capital Management's RPRX Position: Q1 2017 in Review

Prelude Capital Management sold out of Repros Therapeutics Inc. (RPRX) in Q1 2017, closing a stake of 3,700 shares — an estimated $5K sold.

Prelude Capital Management first reported a position in RPRX in Q2 2013 and held it in 5 quarters. The position peaked at $86K in Q3 2013. 33 funds tracked by Wall St. Rank hold RPRX as of Q1 2017.

Prelude Capital Management reported no remaining Repros Therapeutics Inc. position as of Q1 2017 after selling out during the quarter.
Prelude Capital Management sold 3,700 Repros Therapeutics Inc. shares in Q1 2017, an estimated $5K.
Prelude Capital Management first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 5 quarters.
Prelude Capital Management's Repros Therapeutics Inc. position peaked at $86K in Q3 2013.
33 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2017.

Based on Prelude Capital Management's 13F filing for Q1 2017, filed 15 May 2017.